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Abstract: Short-term expression of transgenes is one of the problems frequently associated 
with non-viral in vivo gene transfer. To obtain experimental evidence for the design of 
sustainable transgene expression systems, the contribution of epigenetic modifications to 
the decline in transgene expression needs to be investigated. Bisulfite sequencing and 
reactivation by hydrodynamic injection of isotonic solution were employed to investigate 
methylation statues of CpG in transiently expressing plasmid, pCMV-Luc, in mouse liver 
after hydrodynamic delivery. The cytosines of CpGs in the promoter region of pCMV-Luc 
were methylated in mouse liver, but the methylation was much later than the decline in the 
expression. The expression from pre-methylated pCMV-Luc was insensitive to reactivation. 
Neither an inhibitor of DNA methylation nor an inhibitor of histone deacetylation had 
significant effects on transgene expression after hydrodynamic injection of pCMV-Luc. 
Partial hepatectomy, which reduces the transgene expression from the non-integrated 
vector into the genome, significantly reduced the transgene expression of human interferon 
γ from a long-term expressing plasmid pCpG-Huγ, suggesting that the CpG-reduced plasmid 
was not significantly integrated into the genomic DNA. These results indicate that the CpG-
reduced plasmids achieve prolonged transgene expression without integration into the host 
genome, although the methylation status of CpG sequences in plasmids will not be 
associated with the prolonged expression. 
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Therapeutic effects of in vivo gene therapy depend on the spacio-temporal distribution of the 
transgene products. The most important parameter associated with the in vivo gene transfer of 
secretory proteins is the temporal profile of the transgene expression or, in other words, the level and 
duration of the expression [1,2], because the number of transfected cells would be of less importance 
for secretory proteins compared with intracellular proteins. The level and duration of the expression 
are the results of complicated intracellular events, including transcription and translation, and the 
mechanisms underlying them have not fully been explored yet. The development of hydrodynamic 
delivery of naked plasmid DNA has almost solved the problem of low level of transgene expression as 
demonstrated in a comparison with adenoviral vectors [3]. Unfortunately, hydrodynamic injections are 
frequently associated with transient transgene expression, especially when using plasmid vectors 
containing cytomegalovirus (CMV) promoter, one of the strongest promoters used to date. 
Short-term expression can be due to the degradation or clearance of plasmid DNA. Because plasmid 
DNA consists of natural phosphodiester deoxypolynucleotides, it is easily degraded by DNases. 
Kawabata et al. reported that naked plasmid DNA degrades in mouse blood with a half-life of less than 
10 min [4]. However, plasmid DNA could exist for a long period of time once it has entered into the 
nucleus. It has been reported that plasmid DNA is present in the nucleus of mouse liver for at least  
28 days after in vivo gene transfer even when the transgene expression from the plasmid DNA has 
almost ceased [5,6]. In addition, silenced transgene expression can be reactivated by several stimuli, 
including viral infection, ischemia reperfusion, and hydrodynamic injections, even 6 months after the 
original in vivo gene transfer [2,7–9]. Integration of plasmid DNA into the genome would also result in 
a sustained transgene expression [10]. These experimental results indicate that the degradation of 
plasmid DNA is not a major mechanism at least for the rapid decline in transgene expression observed 
within several days of gene transfer. 
The presence of silenced or inactive plasmid DNA suggests some mechanisms that inhibit transgene 
expression from plasmids in the nucleus. One of the most frequently discussed mechanisms is the 
methylation of deoxycytidyl-deoxyguanosine (CpG) dinucleotides in plasmid DNA [11]. Yew et al. 
developed the GZB plasmid vector in which a synthetic CMV promoter/enhancer with no CpG 
sequences was used to drive cDNA [12]. In addition, we reported that a plasmid expressing murine 
interferon (IFN)-γ under the control of CpG-free human elongation factor (EF)-1 promoter produced a 
sustained level of IFN-γ compared with that with a CMV promoter after hydrodynamic injection into 
mice [13–18]. Another suggested mechanism includes the interaction of histones with plasmid DNA. 
Genomic DNA binds to histones or other nuclear proteins in the nucleus to form the nucleosome [19]. 
Deacetylation of histone has also been suggested to be involved in the decline of transgene expression 
from plasmid vectors [20]. Finally, if plasmid vectors were inserted into the genome, the expression 
might be controlled differently from the expression from episomal plasmid vectors. 
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To answer these questions, we have examined whether epigenetic modifications take place in 
plasmid vectors that have been delivered to mouse liver. The methylation status of the plasmids has 
been evaluated, and the involvement of histone deacetylation and the integration into the genome have 
been examined in mice. 
2. Experimental Section 
2.1. Mice 
Four-week-old male ICR mice, approximately 20 g in body weight, were purchased from Japan 
SLC, Inc. (Hamamatsu, Japan), and were maintained under conventional housing conditions. The 
protocol for the animal experiments was approved by the Animal Experimentation Committee of 
Graduate School of Pharmaceutical Sciences, Kyoto University (the protocol number, #2010-17; 
approval date, 10 March 2010). 
2.2. Plasmid DNA 
pcDNA3.1 and pcDNA3 were purchased from Invitrogen (Carlsbad, CA, USA) and pCpG-mcs was 
obtained from InvivoGen (San Diego, CA, USA). pCMV-Luc and pCpG-Luc were constructed as 
previously reported [13,21]. pCpG-Huγ was constructed by inserting the BglII/NheI human IFN-γ 
cDNA fragment amplified by PCR into the BglII/NheI site of pCpG-mcs [22]. pCMV-Huγ was 
constructed by inserting the human IFN-γ fragment from pCpG-Huγ digested by StuI/NheI into the 
EcoRV/XbaI site of pcDNA3. The plasmids used in this study are summarized in Table 1. 
Table 1. Plasmid DNA used in this study. 
Plasmid Promoter Backbone cDNA 
pCMV-Luc CMV pcDNA3.1 Luciferase 
pCpG-Luc EF1 pCpG-mcs Luciferase 
pCMV-Huγ CMV pcDNA3 Human IFN-γ
pCpG-Huγ EF1 pCpG-mcs Human IFN-γ
2.3. In Vivo Gene Transfer and Reactivation of Transgene Expression 
For gene transfer to the liver, mice received a tail vein injection of plasmid DNA dissolved in a 
large volume of saline (8% volume of body weight) over 5 s [23]. In some cases, mice received 
another large volume injection of saline (8% volume of body weight) over 5 s to reactivate the silenced 
expression in mouse liver [2]. 
2.4. Luciferase Assay 
At indicated periods after injection, mice were killed, and the livers were harvested and 
homogenized in 5 mL/g of a lysis buffer (0.1 M Tris, 0.05% TritonX-100, 2 mM EDTA, pH 7.8). The 
homogenates were centrifuged at 10,000× g for 10 min at 4 °C. Then, 5 μL of each supernatant  
was mixed with 50 μL luciferase assay buffer (Picagene, Tokyo Ink, Tokyo, Japan) and the 
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chemiluminescence was measured with a luminometer (Lumat LB 9507, EG&G Berthold, Bad 
Wildbad, Germany). 
2.5. Extraction of DNA 
DNA was extracted from liver using a DNeasy Blood and Tissue Kit (QIAGEN, Hilden, Germany) 
according to the manufacturer’s instructions. 
2.6. Methylation of Cytosine Residues in Plasmid DNA 
Plasmids (pCMV-Luc, pCpG-Luc) were treated with SssI CpG methylase (New England Biolabs, 
Ipswich, MA, USA), which methylates cytosine residues of CpG dinucleotides. Mock-methylated 
plasmids, which were treated in the same manner as methylated ones without addition of the methylase, 
were used as controls. 
2.7. Bisulfite Sequencing 
Methylation of plasmid DNA was determined by bisulfite sequencing [24]. Bisulfite modification 
was performed on samples containing 1 μg DNA (including genomic DNA and plasmid DNA) 
extracted from mouse liver using BisulFast® DNA modification kit (TOYOBO, Osaka, Japan) 
according to the manufacturer’s instructions. PCR primers were designed by changing all non-CpG 
cytosine residues in the sequence to thymine residues in order to amplify the bisulfite-treated  
DNA. Primers were selected from regions with no CpG nucleotides to amplify the methylated and 
unmethylated DNA equally. The following primers gave efficient and specific amplification of a  
part of the CMV promoter of pCMV-Luc containing 20CpGs: forward, 5′-GTTAATAGGG 
ATTTTTTATTGA-3′; reverse, 5′-AAACTCTACTTATATAAACCTCCCACC-3′. Similarly, the 
following primers were used for the amplification of a part of the luciferase cDNA of pCMV-Luc 
containing 20 CpGs: forward, 5′-TGTTGGTGTTAATTTTATTTTTTTT-3′; reverse, 5′-CCAAAA 
TATAACCATCCATCCTTAT-3′. Bisulfite-treated DNA was PCR-amplified using TaKaRa Ex Taq 
TM (Takara Bio Inc., Otsu, Japan). Cycling conditions were 5 min at 94 °C, then 40 cycles of 94 °C  
30 s, 54 °C 30 s, 72 °C 30 s for the promoter part; and 5 min at 94 °C, then 40 cycles of 94 °C 30 s,  
55 °C 30 s, 72 °C 30 s for the cDNA part. The PCR products were fractionated on 3% agarose gel and 
PCR products of the expected size were excised from the gel, purified and then cloned into pCR2.1 
TOPO vector (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Between 6–8 
colonies that contained the insert were selected at random for each bisulfite reaction performed  
and sequenced to obtain a representative sampling DNA methylation pattern. The sequences of the 
amplified promoter and cDNA parts of pCMV-Luc were analyzed using a QUMA analysis tool 
(http://quma.cdb.riken.jp). 
2.8. 5-aza-2’-Deoxycytidine and Trichostatin A Treatment 
5-aza-2’-Deoxycytidine (5-AZA) (Sigma–Aldrich, St. Louis, MO, USA) was intraperitoneally 
injected into mice at a dose of 0.25 mg/kg body weight at 0, 2 and 4 days after hydrodynamic injection 
of pCMV-Huγ [25]. Trichostatin A (TSA) (Sigma–Aldrich) was dissolved in 50% DMSO to give a 
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concentration of 1 mg/mL. Mice were given an intraperitoneal injection of TSA at a dose of  
10 mg/kg body weight at 3 days after hydrodynamic injection of pCMV-Huγ. Control mice received 
an intraperitoneal injection of the same volume of the vehicle (50% DMSO). 
2.9. Partial Hepatectomy 
One week after hydrodynamic injection of pCpG-Huγ, mice were anesthetized with Nembutal 
(Dainihon Seiyaku, Osaka, Japan) and a midline incision was made on the abdomen. The left posterior 
lobes were excised to achieve a 37% hepatectomy, and the incision was closed with clips. 
2.10. Measurement of Serum Concentration of Human IFN-γ 
At indicated periods after gene transfer, 50 to 200 µL blood was collected from the tail vein. The 
blood samples were incubated at 4 °C for 2 h to allow clotting and then centrifuged at 8000× g to 
obtain serum. The concentration of human IFN-γ in the serum was analyzed by ELISA using 
commercial kits (Human IFN-γ Ready-SET-Go! ELISA kit, eBioscience, San Diego, CA, USA). 
2.11. Statistical Analysis 
Differences were statistically evaluated by Student’s t-test. The level of statistical significance was 
set at p < 0.05. 
3. Results 
3.1. Methylation Status of CMV Promoter and Luciferase cDNA of pCMV-Luc in Mouse Liver 
It was observed that, on average, about 95% of cytosines were methylated in the SssI-treated 
plasmid DNA, whereas no cytosines were found to be methylated in the untreated one (data not 
shown), supporting the validity of the bisulfite sequencing method to estimate the methylation of 
plasmids. Figure 1a shows the methylation status of cytosine residues in the promoter region of 
pCMV-Luc. Few CpGs had been methylated 7 days after injection. On day 14, some of the CpGs in 
the region were detected to be methylated in samples isolated from two out of three mice. Several of the 6 
colonies in the two mice showed methylation with a high frequency of 90%, 90% and 100%, respectively. 
Then, the methylation status in the luciferase cDNA region was examined using the same DNA 
samples used in the above experiments (Figure 1b). The CpGs in this region were hardly methylated at 
least for the first 28 days after gene transfer. 




Figure 1. Methylation status of cytomegalovirus (CMV) promoter (a) and luciferase 
cDNA (b) in pCMV-Luc. Mice were hydrodynamically injected with 100 μg pCMV-Luc. 
DNA was extracted from mouse liver on day 3, 7 14 and 28 after the hydrodynamic 
injection of pCMV-Luc and subjected to bisulfite sequencing. Each circle represents one 
CpG dinucleotide. Six to eight colonies were randomly selected from the liver samples of 
each mouse, and were numbered. CpG # represents the location of CpGs in the amplified 
promoter or cDNA parts, with #1 being the nearest to the 5′-end. The positions that could 
not be read were indicated with X. 
3.2. Correlation of Methylation and Reactivation of Silenced Transgene Expression 
It has been reported that silenced transgene expression is reactivated by hydrodynamic injections of 
isotonic solutions [1,2]. However, it is not clear whether the reactivation is mediated by methylated or 
unmethylated plasmid DNA. To further clarify the correlation of methylation and silenced transgene 
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expression, the reactivation experiment was carried out using both methylated and unmethylated 
plasmids. The pCMV-Luc or pCpG-Luc in either unmethylated or methylated form was injected into 
mice by the hydrodynamic injection method, and a large volume of saline was injected into the mice  
3 days later to reactivate the silenced transgene expression (Figure 2). The level of expression from  
the methylated pCMV-Luc was much lower than that of the unmethylated counterpart, and the saline 
injection resulted in a moderate (about 3.7-fold) increase in the expression. On the other hand, the 
same treatment increased the expression up to about 40-fold when the unmethylated pCMV-Luc was 
administered. The increase in the expression produced by the second saline injection was 3.5- and  
1.9-fold for the unmethylated and methylated pCpG-Luc, respectively. The difference in the luciferase 
activity between unmethylated and methylated pCpG-Luc would be due to the methylation of CpGs in 
the luciferase cDNA. 
 
Figure 2. Reactivation of transgene expression in mouse liver by large-volume injection of 
saline. Methylated or mock-methylated plasmid DNA was hydrodynamically injected into 
mice at a dose of 0.3 pmol/mouse. Three days later, groups of mice received a large-volume 
injection of saline (8% v/w of body weight) to reactivate the transgene expression in the 
liver, and the remaining groups were left untreated. The luciferase activity in the liver was 
evaluated 12 h after the saline injection. The results are expressed as the mean ± SD of four 
mice. * p < 0.05 compared with the untreated group. 
3.3. Effect of 5-AZA on the Transgene Expression of pCMV-Huγ 
The compound, 5-AZA, an inhibitor of DNA methylation, was employed to confirm whether 
plasmid DNA is methylated or not in mouse liver after hydrodynamic injection. pCMV-Huγ (a human 
IFN-γ expressing plasmid) was injected into mice by the hydrodynamic injection method with or 
without intraperitoneal injections of 5-AZA at a dose of 0.25 mg/kg every 2 days. Figure 3 shows the 
concentration of human IFN-γ in the mouse serum after gene transfer. There were no significant 
differences in the levels of human IFN-γ between the two groups, suggesting that pCMV-Huγ is hardly 
methylated during this period. Taken together with the results shown in Figures 1 and 2, it is 
reasonable to conclude that plasmid DNA is hardly methylated in mouse liver after hydrodynamic 
injections at least for the first couple of weeks. 




Figure 3. Effect of 5-aza-2’-deoxycytidine (5-AZA) on the serum concentration of human 
interferon (IFN)-γ after injection of pCMV-Huγ. pCMV-Huγ was hydrodynamically 
injected into mice at a dose of 20 μg/mouse. A group of mice received intraperitoneal 
injections of 5-AZA at a dose of 0.25 mg/kg every 2 days. The concentrations of human 
IFN-γ in the serum were measured at the indicated time points. The results are expressed as 
the mean ± SD of four mice. 
3.4. Effect of TSA on the Transgene Expression of pCMV-Huγ 
To test the possibility of the involvement of histone deacetylation in silenced transgene expression, 
TSA, a histone deacetylase (HDAC) inhibitor, was used, as described in a previous report [26]. In the 
present study, TSA was injected into the peritoneal cavity of mice 3 days after hydrodynamic injection 
of pCMV-Huγ, when the transgene expression had dramatically decreased. The administration of TSA 
had no significant effects on the levels of human IFN-γ (Figure 4). These results exclude the possibility 
that histone deacetylation is involved in the silencing of the transgene expression of plasmids. 
 
Figure 4. Effect of trichostatin A (TSA) on the serum concentration of human IFN-γ after 
injection of pCMV-Huγ. pCMV-Huγ was hydrodynamically injected into mice at a dose of 
20 μg/mouse. On day 3, mice received an intraperitoneal injection of vehicle or TSA at a 
dose of 10 mg/kg. The concentrations of human IFN-γ in the serum were measured at the 
indicated time points. The results are expressed as the mean ± SD of four mice. 
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3.5. Effect of Partial Hepatectomy on the Transgene Expression of pCpG-Huγ 
Partial hepatectomy induces the proliferation of hepatocytes, so that the size of the organ returns to 
normal within 21 days after the surgery [27]. This procedure has been used to discriminate between 
integrated and episomal DNA, because the plasmid integrated into the genome is replicated with the 
proliferation of hepatocytes. Therefore, this technique was used to see whether the pCpG vectors, the 
persistent expressing plasmid DNA, are integrated into the genome after hydrodynamic injection. 
About 37% of the liver was removed 7 days after the hydrodynamic injection of pCpG-Huγ. Figure 5 
shows the concentration of human IFN-γ in the serum of mice with or without partial hepatectomy. 
The concentration in the hepatectomy group transiently increased soon after the partial hepatectomy, 
then decreased with time to a level much lower than that in the control group. The transgene 
expression was about 10% to 20% of that in the control mice at a steady-state 2 weeks after the partial 
hepatectomy. These results indicate that pCpG vectors remain in the episomal form, even though they 
are effective in producing transgenes for a long period of time. 
 
Figure 5. Effect of partial hepatectomy on the serum concentration of human IFN-γ after 
injection of pCpG-Huγ. pCpG-Huγ was hydrodynamically injected into mice at a dose of 
0.1 μg/mouse. On day 7, a group of mice received a partial hepatectomy (indicated with an 
arrow). The concentrations of human IFN-γ in the serum were measured at the indicated 
time points. The results are expressed as the mean + SD of four mice. 
4. Discussion 
The cytosines in CpG dinucleotides in mammalian DNA are mostly methylated by DNA 
methyltransferases. Because the methylation generally reduces the efficiency of gene expression, CpG 
depletion from plasmid vectors has been used to increase the duration of transgene expression [12]. 
We found in the present study that some CpGs in the promoter region of pCMV-Luc were methylated 
on and after day 14 post-injection. However, a great reduction in transgene expression of pCMV-Luc 
after hydrodynamic injection occurs by 3 days [13], when almost no CpG sequences were methylated 
(Figure 1), strongly suggesting that methylation is not the reason for the reduced transgene expression. 
Chen et al. also proved that CpG methylation status did not change after episomal DNA delivery into 
mouse liver [28]. On the other hand, we observed that the CpGs in the cDNA are less methylated than 
those in the promoter region, indicating that the methylation rate depends on the position of the CpGs. 
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Several research groups, including our own, have reported that the level of transgene expression 
from plasmid DNA can be significantly upregulated by some stimuli, including, but not limited to, 
large-volume injection of isotonic solutions, endotoxin, radiation and ischemia/reperfusion. The 
experiments using pre-methylated plasmid DNA showed that methylated plasmid DNA is much less 
sensitive to the reactivation stimulus of a large-volume injection (Figure 2). The levels of reactivated 
transgene expression from methylated pCMV-Luc and pCpG-Luc were lower than those from their 
unmethylated counterparts with no additional injections. Therefore, a significant level of reactivation 
of plasmid DNA by a large-volume injection of saline on day 3 (Figure 2) as well as at later time 
points [2] strongly suggests that pCMV-Luc and other plasmid DNA delivered by hydrodynamic 
injection are less methylated in mouse liver. An in vitro study reported that the intragenic CpG content 
influenced de novo transcriptional activity, but this regulation was not related to the level of CpG 
methylation [29]. Moreover, the administration of 5-AZA, an inhibitor of DNA methylation, hardly 
affected the level of transgene expression from pCMV-Huγ compared with that in the vehicle-treated 
group (Figure 3). Based on the results obtained so far, the major reason for the reduced transgene 
expression of CpG-replete plasmid DNA is not CpG methylation of the plasmid DNA. This is 
consistent with the conclusion made by Chen et al., that transcriptional activity of the transgene 
expression cassette was not influenced by the CpG methylation status of the plasmid bacterial 
backbone [28]. 
Some reports have raised the possibility that histone deacetylation is involved in the reduced 
transgene expression after gene transfer [20,29,30]. It has been reported that acetylated H3 and H4 
histones in mouse liver increased after a single intraperitoneal injection of TSA at a dose of  
10 mg/kg [26], and maximal gene activation occurred at approximately 2–4 h post-injection, with a 
return to base-line by 16 h [26,31]. However, the transgene expression from pCMV-Huγ was unaffected 
by administration of the same dose of TSA (Figure 4). This is consistent with the conclusion of  
another study, in which the relationship of histone modification and transgene expression silencing was 
investigated [5]. Therefore, we believe that the reduced transgene expression from hydrodynamically 
injected plasmid DNA was not directly caused by the deacetylation of histones. 
Another possibility to explain the difference in the duration of transgene expression from CpG-
replete and CpG-reduced plasmids involves the integration of plasmids into the genome. Integration of 
plasmid DNA into host genomic DNA has been challenged using transposon systems [10], because it 
is considered to increase the duration of transgene expression through integration into the host genome. 
It has long been known that the level of transgene expression is not significantly reduced by partial 
hepatectomy when the DNA delivered is integrated into genomic DNA, because hepatectomy-induced 
cell division increases the number of cells that have the integrated DNA [32,33]. However, the results 
of the present study showed that the long-expressing plasmid pCpG-Huγ is hardly integrated into 
genomic DNA (Figure 5). 
The silencing of transgene expression from plasmid DNA should be due to complex intracellular 
events in which multiple factors are involved. Empirical studies have clearly demonstrated that  
the type of promoter, the bacterial backbone [34] and other epigenetic modifications except DNA 
methylation and histone deacetylation, such as histone methylation [35,36], at least partly explain the 
silencing of transgene expression from plasmid DNA. 
  




We have demonstrated that the reduction in the transgene expression is not due to CpG methylation 
or histone deacetylation, and that genome integration is not a reason for prolonged transgene 
expression from CpG-reduced plasmids. These results indicate that the CpG-reduced plasmids are 
effective vectors that achieve prolonged transgene expression without integration into the host genome, 
although the CpG sequences in plasmids are less likely to be methylated in vivo. 
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